Archive for the ‘SBIR and Funding’ Category

Deadlines to Apply for NCATS Funding Opportunities are Coming Up September 6!

August 21, 2016

This is a reminder that the National Center for Advancing Translational Sciences (NCATS) has several open Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) program funding opportunities designed to help advance and commercialize translational research technologies. NCATS encourages applications in these four research areas of interest: drug discovery and development, diagnostics and devices, bioinformatics and information technology, and clinical research.

 

All opportunities below have an application deadline of Sept. 6, 2016, 5 p.m. local time.

 

2016 Omnibus Solicitation

Small businesses, research and technology transfer organizations are eligible to apply for the 2016 Omnibus Solicitation. Applications may address any stage of translation, from target validation through pre-clinical and clinical evaluation to intervention, implementation and dissemination. Review NCATS’ research priorities to determine its areas of interest.

Other Funding Opportunities

SBIR Direct Phase II

Small businesses that have accomplished the objectives of a Phase I SBIR grant through non-SBIR funds are able to apply for SBIR direct-to-Phase II funding. Applicants must demonstrate the scientific and technical merit and feasibility of the prototype stage of developing a biomedical technology that has commercial potential.

  • PAR-15-288: Direct Phase II SBIR Grants to Support Extended Development, Hardening, and Dissemination of Technologies in Biomedical Computing, Informatics, and Big Data Science
  • PAR-14-088: Direct Phase II SBIR Grants to Support Biomedical Technology Development

 

SBIR Technology Transfer

This funding opportunity encourages SBIR grant applications from small business concerns for projects to transfer technology out of the NIH intramural research labs into the private sector.

  • PA-15-354: SBIR Technology Transfer (R43/R44)

 

Platform Delivery Technologies for Nucleic Acid Therapeutics

This funding opportunity is designed to incentivize small businesses to generate new technologies and products for delivering nucleic acids into cells and tissues for the purpose of treatment or prevention of human disease.

  • PA-14-307: Platform Delivery Technologies for Nucleic Acid Therapeutics (R43/R44)
  • PA-14-308: Platform Delivery Technologies for Nucleic Acid Therapeutics (R41/R42)

 

Development of Appropriate Pediatric Formulations and Drug Delivery Systems

Applications must address different and complementary research needs for the development of appropriate pediatric drug formulations in different age groups.

  • PAR-13-345: Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R43)
  • PAR-13-346: Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R41)

 

Learn more about current funding opportunities for small business at NCATS Small Business, including eligibility requirements and research priorities. Need help? Contact NCATS SBIR and STTR to discuss your project idea.

 

Connect with NCATS! Like us on Facebook and follow us on Twitter. Use #NCATSsbir and join the online conversation.

 

***

NCATS’ SBIR and STTR programs are engines of innovation for developing and commercializing tools, technologies and intervention platforms to support the creation of new therapeutics and diagnostics. SBIR and STTR are government set-aside programs for domestic small businesses to engage in research and development that has the potential for commercialization and public benefit.

NCI FY2017 Contract Topics Now Available

August 3, 2016

FY2017 Contract Topics Now Available!

The National Cancer Institute Small Business Innovation Research (NCI SBIR) Development Center funding opportunities come in two large categories: grants and contracts. Contracts are legally binding agreement for the direct use or benefit of the Government, and involve deliverables at the end. This year, there are 15 contract topics in high priority research areas ranging from therapeutics to digital health. See below or visit our website to find out more about this year’s topics. Proposals are due by October 21, 2016, 5:00 PM EDT.  Please direct all questions regarding contracts to the NCI Office of Acquisitions (ncioasbir@mail.nih.gov).

INFORMATION

SOLICITATION      TOPICS      SUBMIT PROPOSAL      QUESTIONS


PRE-PROPOSAL WEBINAR

August 24, 2016, 2:00 PM EDT

REGISTER

The session will cover:
PHS2017-1 Solicitation
Contract Topics per IC
Electronic Contract Proposal Submission (eCPS) Website


For more information about the NCI SBIR & STTR Programs, please visit the website.

The SBIR & STTR Programs are NCI’s engine of innovation for developing and commercializing novel technologies and products to prevent, diagnose, and treat cancer. The SBIR & STTR Programs are government set-aside programs for domestic small businesses to engage in research and development that has the potential for commercialization and public benefit.

Sign up to receive updates about SBIR & STTR funding opportunities at sbir.cancer.gov.

 

NCI SBIR/STTR Webinar & Great Funding Opportunity by JLABS!

July 8, 2016

The National Cancer Institute Small Business Innovation Research (NCI SBIR) Development Center will be participating in the Women in Biotech webinar on Tuesday, July 14, 2016. NCI SBIR Program Staff Kory Hallett, Ph.D. will be speaking at the webinar about NCI SBIR/STTR funding opportunities and application tips. Register today for this free webinar and get in-depth information about SBIR and STTR programs.

In addition to the webinar, we would like to share with you a great funding opportunity that could help fuel your cancer research. The JLABS QuickFire Challenge will award up to $500,000 in a research grant and entrance to JLABS. We hope you find the contest useful for advancing your cancer research. Detailed information about the webinar and the QuickFire Challenge can be found below.

If you have any questions about the webinar or the NCI SBIR/STTR programs, please send us an email at ncisbir@mail.nih.gov.

Securing SBIR and STTR Funding: Support for Women
Entrepreneurs and Researchers in Biotech

Thursday, July 14, 2016, 1:00 – 2:00 p.m. ET | 10:00 – 11:00 a.m. PT

Register Today

Speakers:

  • Kory Hallett, Ph.D., Program Staff, AAAS Science & Technology Policy Fellow, NCI, NIH
  • Cartier Esham, Ph.D., Executive Vice President, Emerging Companies, Biotechnology Innovation Organization (BIO)
  • Lili M. Portilla, M.P.A., Director, Strategic Alliances, NCATS, NIH
  • Stephanie Fertig, M.B.A. Director, NINDS Small Business Programs, NIH

The webinar will feature:

  • An overview of SBIR and STTR programs and funding opportunities
  • Examples and case studies of women founders of bio- and healthcare-technology early-stage businesses

Tips and tools for applying for funding, and resources available for women entrepreneurs and researchers from socially and economically disadvantaged backgrounds

 

JLABS QuickFire Challenge

[APPLY HERE]

Johnson & Johnson Innovation and Janssen Pharmaceuticals, Inc. aim to improve the health and wellness of people around the world. To that end, there is a passionate and engaged workforce across the consumer, medical device and pharmaceutical units who are interested in finding and deploying comprehensive, end to end, integrated solutions which take into account the world in which we live today. Johnson & Johnson Innovation and Janssen Pharmaceuticals, Inc. are bringing together the consumer, medical device and pharmaceutical sectors to award a prize or a series of prizes to the person or team(s) who submits the best idea, technology, or solution that will address a critical health need for the world’s population. Please check out the areas of interest, with an emphasis on lung cancer and metabolism.

Solutions will be evaluated based on their ability to meet the following criteria:

  • Address a particular cohort with a critical unmet medical need in strategic areas of interest, such as lung cancer and metabolic diseases.
  • Integrate a novel approach that combines pharmaceutical, devices and/or consumer health solutions.
  • Address part or all of the spectrum of prevention, interception and cure.
  • Outline how the award would help them reach a critical milestone within the time frame of a single year and provide a full “time-to-market” plan for their solution.

The deadline to apply is August 31, 2016, and winners will be announced by the end of the year.

Thomas Medical Receives Indy Chamber GoGlobal Grant to Support Export Growth

June 3, 2016

IMG_1946_edit

[Indianapolis] — Thomas Medical has been awarded one of the Indy Chamber’s first GoGlobal grants, a new program in partnership with JPMorgan Chase to recognize and support the efforts of local employers to begin or expand exporting activity. To earn the competitive grant, Thomas Medical shared specific, practical plans to increase international sales over the next year.

“Thomas Medical is thrilled to be awarded a GoGlobal Grant from the Indy Chamber,” said Ben Ovenden, Sales Manager for Thomas Medical. “The incremental expenses associated with export growth can be prohibitive for smaller companies, so reaping the benefits of exporting, such as job growth, can seem daunting. Support like the Indy Chamber’s Global Indy Initiative goes a long way to keeping local companies on the global market.”

 
The grant announcement was made at the Indy Chamber’s 2016 World Trade Day, an annual event highlighting the impact of global trade and investment in the Indianapolis region. Exports and foreign investment support more than 100,000 local jobs, with Indianapolis companies selling nearly $15 billion in goods and services outside the U.S. last year.

 
“Indy ranks 23rd out of the 100 largest metro areas in total exports, but the successful exporters in our community are far outnumbered by companies who aren’t taking advantage of global opportunities,” said Michael Huber, president and CEO of the Indy Chamber. “With the support of JPMorgan Chase, the GoGlobal grant program will help businesses explore new markets and find new customers around the world – and inspire others to follow suit.”

 

Thomas Medical will use the grant funds to participate in the annual meeting of the European Society of Human Reproduction and Embryology (ESHRE), July 3-6 in Helsinki, Finland.

 
The GoGlobal Grant awards are part of the Indy Chamber’s Global Indy initiative, which exists to encourage the Indy metro’s companies to engage in global opportunities through export support and facilitating foreign direct investment activity.

 
For more information about the GoGlobal Grant awards, visit IndyChamber.com/GoGlobalGrant.

IHIF Annual Meeting Convenes Industry Leaders

May 16, 2016

Cancer Moonshot and Strategic Plan Anchor Agenda

Contact: Kristin Jones, President and CEO
Indiana Health Industry Forum
kjones@ihif.org or 317-686-0994

INDIANAPOLIS (May 9, 2016) — The Indiana Health Industry Forum is kicking-off its 2016 Annual Meeting and conference for the state’s life science industry today.  The event’s opening reception and VIP Dinner will take place at the Alexander Hotel – a Dolce Property in downtown Indianapolis.   For the third year, the reception will feature a student research poster display highlighting some of the biomedical student projects from the McKenzie Center for Innovation and Technology.  Tuesday’s meeting will take place at the Eli Lilly and Co. headquarters in conjunction with the company’s 140th Anniversary celebration.

The conference keynote speaker will be Michael Weingarten, the director of the National Cancer Institute’s SBIR grant program.  His presentation will cover SBIR best practices, a discussion of the agency’s translational services, programs, and awards, tips on writing a successful application, and touch on the agency’s role in the national Cancer Moonshot initiative.  A follow-on panel will further explore Indiana’s Contribution to the Cancer Moonshot.  Panelists will include: Representative Larry Bucshon, M.D, (IN 8th); Dr. Sherry Harbin, Geniphys; Bryan Hannon, American Cancer Society; Dr. Mervin Yoder, IU School of Medicine, and Scott Shortenhaus, Eli Lilly and Co.  The panel moderator will be Deborah Pollack-Milgate with Barnes & Thornburg.

IHIF will also be kicking off Roadmap 2020 and beginning collection of recommendations for the development of the next industry driven strategic plan.  More information on Roadmap 2020 and how to submit recommendations for consideration can be found on the IHIF website at www.ihif.org/pages/roadmap2020.  A panel discussion covering trends in strategic plan topic areas will include remarks from: Sue Ellspermann, Former Lt. Governor of the State of Indiana , Roger Harvey, Bose Public Affairs Group; Alex Smith, Deloitte; Calvin Thomas IV, Ivy Tech Corporate College; and Matthew Waninger, Ph.D., MED Institute.   The panel will be moderated by Eric Marr, Founder and President of Diversity Accords and current chair of the IHIF Board of Directors.

IHIF would like to thank the following sponsors for their support:  Headline Sponsor: Eli Lilly and Co., Gold Sponsors: Barnes & Thornburg and Cook Medical, Silver Sponsors: CAI and Hoosiers Work for Health, Event Sponsors: Konica Minolta and ShareVault.  IHIF would also like to recognize some of our partners: The Catherine Peachey Fund in support of the Komen Tissue Bank, Lodestone Insights, Cabello Associates, and the BIO Business Solutions Program.

About IHIF

The Indiana Health Industry Forum (IHIF) is a statewide trade association representing members of Indiana’s health science business community.  The diverse members of IHIF generate the collective voice of the state’s health and life science industry.  Our mission is to connect key stakeholders to: enhance business networks, advocate for member interests, develop workforce skills, and provide strategic vision in the interest of growing the state’s health industry economy and reputation.  For more information and to become a member, please visit www.ihif.org

Introducing New IHIF Member Benefit Program for Workwear and Facilities Services

February 15, 2016

BBS 2012

We are excited to announce that the Indiana Health Industry Forum (IHIF) and BIO Business Solutions are now offering our members a new benefit program through UniFirst Corporation. This program can help you save on a wide selection of uniforms, lab coats, and other clothing items for rental programs or for direct purchase. The UniFirst partnership will also extend to program offerings from UniClean, a single-source provider for all cleanroom and controlled environment garment-related needs. Similar rental programs are also in place for facility service products and microfiber cleaning supplies.

This savings program is the result of collaboration between Indiana Health Industry Forum and the Biotechnology Innovation Organization (BIO), the world’s largest biotechnology trade association.

Member companies of IHIF can realize the benefits from UniFirst’s services through this program, which include:

  •  Uniform and facility service savings of 30-50%
  •  Hygienically clean garments
  •  Dedicated customer service team
  •  3-year fixed pricing
  •  Free lab coat pressing included with rental program
  •  Free company and name emblems on initial installation
  •  No upfront program investment
  •  1 week complimentary service upon new agreement

Want to learn more?

Please click here to complete a brief survey to help assess your company’s needs and interest in UniClean/UniFirst.

For more information about the UniClean/UniFirst programs or to enroll for member savings, please visit bio.org/bbs/unifirst or bio.org/bbs/uniclean.
Learn more about other Savings Solutions and special offers available to you exclusively through your membership in IHIF.  Click here

October 2016 Life Science Lunch – The Power of Normal

October 29, 2015
“The Power of Normal: Using Normal Controls in Breast Cancer Research”

October 20, 2015

October is Breast Cancer Awareness Month!  IHIF and Barnes & Thornburg are pleased to present a special program highlighting important new research in the field.  The program will feature speakers from the Susan G. Komen Tissue Bank, a valuable biorepository right here in Central Indiana containing high quality normal breast tissue and blood samples for research and leading researchers who have used these samples to investigate new diagnostic tools and therapies.  Learn how to access the samples and why they play a critical role in the search for a cure.

Special introduction by The Catherine Peachey Fund

The Catherine Peachey Fund is a consumer-focused group of advocates fighting for a cure for breast cancer.  This 100% volunteer organization has funded more than $2.5 million dollars of breast cancer research in Indiana over the past twenty years.  You can help them fund research by purchasing Just Peachey: Bearing Fruit Cookbook.  Included in this beautiful, hard-cover book are over 500 recipes, along with a completely updated “Pink Pages” section with excerpts from The Mayo Clinic Breast Cancer Book.  The production costs of this book have been underwritten, so that 100% of cookbook sales can be granted to important breast cancer research in Indiana.  Share Just Peachey: Bearing Fruit Cookbook as a gift for corporate clients or employees by taking advantage of this Special Promotion:  50% off Case Purchases (20 books per case).  The discounted price is $249.90 or only $12.50 per book when purchasing a full case of cookbooks.  Give a lasting and meaningful gift that supports breast cancer research right here in Indiana! – visit PeacheyFund.org for more information.

Panelists From:
Jill Henry, COO

Susan G. Komen Tissue Bank

Hari Nakshatri, Ph.D.
Milan Radovich, Ph.D.
Natascia Marino, Ph.D..

IU Simon Cancer Center

Stephanie Rufenbarger-Lesher

The Catherine Peachey Foundation

Moderator:

Kristin Jones

Indiana Health Industry Forum

About the Series

The Indiana Health Industry Forum and Barnes & Thornburg LLP partner to present a monthly seminar series on critical issues in life science. Each month, at lunch, a policymaker or a panel in the field of life science will be available to answer questions concerning the major challenges and opportunities in the life science industry. We hope you will join us.

There is no charge to attend, but please register so we know how many lunches to order. Please see registration page for details. Some of the discussion questions will be submitted to the speakers in advance.

For information on upcoming programs, please visit the Life Science Lunch website – http://www.ihif.org/pages/lifescience

Boehringer Ingelheim Day with MassBio

September 23, 2015

Boehringer Ingelheim Day with MassBio

2:00 – 7:30pm

MassBio and Catalyst restaurant at 300 Technology Square, Cambridge, MA 02139

October 8th, 2015

 

The Indiana Health Industry Forum has been invited to submit member profiles for consideration in the Boehringer Ingelheim Pharma Days program.  This event will be held in Boston, October 8th and is organized by MassBio – IHIF’s counterpart organization in Massachusetts.  If you would like to be considered for a one-on-one meeting with Boehringer Ingelheim, please submit a one-pager describing your program of interest to Kristin Jones at IHIF (kjones@ihif.org) by September 30th.  Please do not disclose confidential information. If selected, you must be able to travel to Boston on October 8th to participate in the meetings.

 *****

Please join us on Thursday, October 8th, 2015 for a private meeting and reception with a select group of MassBio members and senior leaders from Boehringer Ingelheim.

Boehringer Ingelheim will provide an overview of its Research & Development organization, Venture fund, therapeutic areas of interest and models for early and late stage licensing partnerships. There will be an opportunity to request one–to-one meetings. A poster competition and pitch contest will take place and a networking reception will follow the program. An innovation prize will be awarded to the winning start-up from the pitch contest at the reception.

One-on-one meetings may be requested by participants.

Boehringer Ingelheim will have teams within the following areas participating in one-on-one meetings: CNS, Oncology, Cardiometabolic, Immunology, Respiratory, Hearing loss, Microbiome, Regenerative medicine and Gene medicine.  For more details, see list below.

Agenda:

2:00 – 3:00pm               Registration and Poster presentation vote for Innovation Prize

Attendees will receive Massbio Dollars to invest into the top 3 most innovative technologies presented.

 

3:00 – 3:05pm               Welcome by MassBio Robert K. Coughlin, President and CEO at MassBio

 

3:05 – 3:30pm            Boehringer Ingelheim Partnering – Working Together for Better Health

  • Paola Casarosa, Corp VP, Business Development & Licensing/ Prescription Medicines

 

3:30 – 4:00pm            Discovery Research and External Innovation

  • Clive Wood, Corp Senior VP, Discovery Research

 

4:00 – 4:30pm            Boehringer Ingelheim Corporate Venture Fund

  • Frank Kalkbrenner, VP, Head of the Boehringer Ingelheim Venture Fund

 

4:30 – 5:00pm               Innovation Prize pitches and judging

 

5:00 – 5:30pm               Boehringer Ingelheim closing remarks and Q&A

 

5:30 –7:00pm                Reception – Catalyst
Innovation Prize winner will be announced at the reception

 

This event, part of the MassBio Pharma Day Series, will provide a great opportunity to network with Boehringer Ingelheim licensing and therapeutic area leaders and learn how a biopharmaceutical company evaluates external research and approaches licensing and partnerships.

 

Current Areas of Interest:

 

    • Central Nervous System
  • Alzheimer’s disease
  • Schizophrenia (focus: negative symptoms and/or cognitive impairment)
  • Depression (focus: treatment-resistant depression)
  • Impulse control disorders

Out of scope: Monoamine uptake inhibitors or monoamine receptor modulators, Compounds with undefined mechanism of action

    • Oncology
  • For clinical stage opportunities: Focus on lung cancer and haematology – irrespective of the MoA
  • Up to IND-ready stage:
  • Cancer cell -directed therapies
    • Growth signaling
    • Apoptosis regulation
    • Epigenetic regulation
    • Protein homeostasis
    • Additional areas of focus will emerge from scientific breakthroughs in cancer biology (e.g. genome integrity, splicing, protein translation, stem cell / developmental pathways, miRNAs)
  • Immune cell -directed therapies
    • Immune cell re-activation
    • Immune cell re-direction
    • Immune cell priming
    • Increased focus in the future will be on lymphocyte trafficking

 

  • Immunology
    • Crohn’s disease and ulcerative colitis
    • Systemic lupus erythematosus (including lupus nephritis)
    • Rheumatologic disorders such as RA (limited to mechanisms that show superior efficacy compared to current standard of care) and spondyloarthritis
    • Systemic sclerosis-scleroderma

Out of Scope: Microbial therapeutics and Gene therapy

 

  • Cardiometabolic
    • Chronic Kidney Diseases and Diabetic Nephropathy
    • Diabetic Retinopathy
    • NASH (Nonalcoholic steatohepatitis) and liver fibrosis
    • Obesity (CV-benefit and patient relevant weight loss >10%)
    • Type 2 Diabetes (evidence for disease modification, CV-risk reduction and/or significant weight reduction)

 

  • Respiratory
    • Chronic Obstructive Pulmonary Disease
    • Asthma
    • Interstitial Pulmonary Fibrosis
    • Cystic Fibrosis
    • Acute Lung Injury or Acute Respiratory Distress Syndrome

 

  • Research Beyond Borders
  • Microbiome:
    • Novel bacteria/bacterial products and their causal role in human health & disease (esp. related to autoimmune, CNS, oncology  and cardiometabolic disorders)
    • Microbiome triggers which impact host immune/inflammatory response & barrier function Depression (focus: treatment-resistant depression)
    • Elucidation of associated pathways & discrete targets (both host & microbiome-derived) for therapeutic intervention
  • Regenerative Medicine:
    • Molecular understanding of mechanisms involved in tissue degeneration
    • New targets or methods for identifying targets that are implicated in the mobilization and/or differentiation of endogenous stem cells/progenitor cells
    • Approaches that may modulate muscle/bone/cartilage degeneration, and/or neurodegeneration
  • Gene Therapy:
    • Rare diseases with high unmet medical need as entry, enabling BI to become a leader in the field; including proprietary assets available for potential partnering
    • Technology platform development, focusing on inducible system for regulatable expression of therapeutic products in the context of AAVs, ensuring applicability of gene therapies in nonlife-threatening diseases
  • Hearing Loss:
    • Understanding of mechanisms involved in hearing loss and approaches with potential to restore hearing or reduce loss
  • Age-related, as well as noise and drug-induced hearing loss

 

 

 

Boehringer Ingelheim Attendees:

 

Dr. Paola Casarosa, Corp. VP, Bus. Dev. & Licensing/Prescription Medicines

Dr. Monica Cheng, Global Licensing, Cardiometabolic Diseases, Bus. Dev. & Licensing/Prescription Medicines

Dr. Laurie Churchill, Global Head Immunology, Bus. Dev. & Licensing/Prescription Medicines

Dr. Henri Doods, VP, Research Beyond Borders

Dr. Jay Fine, Vice President & Global Therapeutic Area Head Immunology and Respiratory Diseases Research

Dr. Christine Grygon, Executive Director, Bus. Dev. & Licensing/Prescription Medicines

Dr. Martin Heidecker, Head of Venture Fund USA

Dr. Jullian Jones, Global Licensing, Oncology

Dr. Frank Kalkbrenner, VP, Venture Fund

Dr. Cyrille Kuhn, Executive Director, Head of Research Beyond Borders

Dr. Michael Mark, Global Head CardioMetabolic Diseases Research

Dr. Klaus Mendla, Global Head CNS, Bus. Dev. & Licensing/Prescription Medicines

Mr. Imran Nasrullah, Innovation Sourcing, Bus. Dev. & Licensing/Prescription Medicines

Dr. Chad Nivens, Global Head Respiratory, Bus. Dev. & Licensing/Prescription Medicines

Mr. Andrew Owenson, Corp. SVP, Therapeutic Area Head Respiratory

Dr. Michel Pairet, Corp. SVP, R&D non-clinical

Dr. Glyn Parkin, Corp. SVP, Therapeutic Area Head Cardiometabolic Diseases

Dr. Mark Pearson, VP, New Therapeutics Concept Discovery

Dr. Jan Poth, Therapeutic Area Head Immunology & Vice President Marketing, Pipeline Products

Mr. Ralph Mark, Director, External Partnerships and Financial Strategy

Dr. Juergen Reess, Therapeutic Area Head CNS

Dr. Oliver Reuss, Head of Business Model & HealthCare Innovation

Dr. Ioannis Sapountzis, Global Head Oncology, Bus. Dev. & Licensing/Prescription Medicines

Prof. Dr. Gerd Schnorrenberg, Senior Executive Advisor, R&D non-clinical

Dr. Margrit Schwarz, VP, Cardiometabolic Diseases Research

Dr. Peter Seither, Senior Manager, Scientific Collaborations

Dr. Bernd Sommer, Head of CNS Research

Dr. Georg van Husen, Therapeutic Area Head Cardiovascular

Dr. Clive Wood, Corp. SVP, Discovery Research

Dr. Johannes Zanzinger, Global Head Cardiometabolic Diseases, Bus. Dev. & Licensing/Prescription Medicines

 

CPPH FALL CONFERENCE: POWER PARTNERING & PLANNING SESSION

September 8, 2015

Hosted by Telamon

Event to be held at the following time, date, and location:

Wednesday, September 23, 2015 from 12:00 PM to 4:30 PM (CDT)

Pottawattomie Country Club
1900 Springfield Avenue
Michigan City, IN 46360

Attend Event

Agenda Announced!

Did You Know?

IN House Bill 1004 Safety PIN Program passed in May 2015 provides for a $10M+ grant and call for proposals to reduce Indiana’s infant mortality rates. Telamon’s fall CPPH conference will be THE power format for partnership creation, program discovery, and next steps planning.

We look forward to engaging with you!
(If you don’t work directly with infants or moms, please still attend. Programs for health and care acess are interdependent. We want you to share!).

FIRST HALF: Power of Perspectives, Policy, & Partnership! State of the State.

11:45am = Registration & Buffet Lunch
12:00pm = Telamon, The Power of Partnership & Planning: Welcome, Intro, & Purpose.
12:15pm = Power of Perspective: Literally Redefining HealthCare – Format: Group Share, Objective: Share. Listen. Understand.
1:00pm = Power of Policy: Major Public Health Concerns in State – Format: Keynote Speaker, Objective: Defining the Problem. Policy Updates.
1:30pm = Power of You. Your Impact. Your Organization. – Format: Group Share, Objective: Share. Listen. Partner.
2:15pm = Power of Presence: Networking for Partnership – don’t forget your business cards!

SECOND HALF: Power of Place, Data, & Opportunity. Topic Specific: Infant Mortality.

2:30pm = Power of Place: Indiana Youth Institute (IYI) – Format: Speaker – Stephen Gil, Northwest Indiana Outreach Manager
2:45pm = Power of Data: Black Infant Mortality – Format: Speaker – Julie Whitman, VP of Programs, IYI. Objective: Data Share.
3:30pm = Power of Opportunity: State Safety PIN Request for Proposal – Format: Speaker
4pm = Power of Partnership: Wrap-Up & Next Steps
4:30pm = Adjourn with Enthusiasm for Further Action & Partnering!

Attend Event

Funding for Parkinson’s Research

September 2, 2015

The Michael J. Fox Foundation (MJFF) is accepting pre-proposals for funding of Parkinson’s disease research, including from biotech and pharmaceutical companies. Of the more than $525 million to research programs MJFF has funded since 2000, $110 million in non-dilutive capital has been allocated to industry projects.

The Foundation supports research toward Parkinson’s target advancement, therapeutic development (symptomatic and disease-modifying), and improved biomarkers and outcome measures. The pre-proposal deadline is October 28.

Visit https://www.michaeljfox.org/research/apply-for-grant.html to learn more and download application instructions.